Data from UALCAN indicate that increased expression of CCL5 and CCR5 is associated with a trend towards poorer prognosis for AML patients (CCR5 p = 0.071; CCL5 p = 0.068) [23,24]. This evidence concerns the gene CCR5 and acute myeloid leukemia.